AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study: Lp-PLA2 predicts coronary heart disease.
2004 MAR 4 - (NewsRx.com & NewsRx.net) -- A prospective, case cohort study of the atherosclerosis risk in communities (ARIC) population supports the measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) to help identify individuals at risk for coronary heart disease (CHD).
The research team, led by researchers at Baylor College of Medicine and Methodist DeBakey Heart Center, examined the relationship between Lp-PLA2, C-reactive Protein (CRP), traditional risk factors, and the risk for a CHD event over the course of 6-8 years stratified by low-density lipoprotein (LDL) cholesterol.
The findings appeared in the online version of Circulation, the journal of the American Heart Association.
The results of the study show mean levels of Lp-PLA2 and CRP were higher in the 608 men and women who developed CHD events than a matched group of 740 individuals who remained free of CHD, after adjustment for age, sex, and race. The study also determined that for individuals with LDL cholesterol below the median (130 mg/dL), both Lp-PLA2 and CRP were significantly and independently associated with CHD in fully adjusted models. Individuals with normal LDL levels (
"In the current guidelines, drug therapy is not recommended in primary prevention of CHD for individuals with LDL cholesterol below 130 mg/dL. However, in the ARIC population, one-third of all coronary events occurred in individuals with LDL below these levels, which is consistent with observations in other clinical studies," said Christie M. Ballantyne, MD, director of the Center for Cardiovascular Disease Prevention at Baylor College of Medicine and the Methodist DeBakey Heart Center, Houston, Texas, and lead author of the study. "Novel blood tests to measure Lp-PLA2 and high-sensitivity CRP help assess CHD risk in patients with low LDL ...
- Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for...
- Press release article from: PR Newswire January 29, 2008 700+ words
...shown to lower LDL cholesterol and Lp(a) and to promote weight loss. Lp(a) is a lipoprotein...from the body. LDL Cholesterol, Cardiovascular...people with high LDL cholesterol, some patients...obesity, high Lp(a) and high...
- New Lower LDL Cholesterol Guidelines for Patients at Risk for Heart Disease...
- Press release article from: Business Wire July 14, 2004 700+ words
...Significantly Improves LDL Cholesterol Risk Assessment What...detailed measurements of LDL cholesterol, improving on routine...atherogenic LDL subclasses Lp(a), intermediate...risk factor known as LDL cholesterol size pattern. Recognized...
- QuatRx Pharmaceuticals Initiates Phase I Trial for Treatment to Reduce Both LDL...
- Press release article from: PR Newswire September 28, 2006 700+ words
...significantly reduced LDL cholesterol and Lp(a). To date, there...commonly used to lower LDL cholesterol and reduce the risk of...many people with high LDL cholesterol, statins have no effect on Lp(a), can cause many...
- How Far to Lower LDL Cholesterol: Important New Data.
- Magazine article from: Clinical Cardiology Alert April 1, 2001 700+ words
...Synopsis: Aggressive LDL cholesterol lowering of at least...achieved these levels. Lp(a) levels decreased...Changes in HDL and Lp(a) did not correlate...conclude that aggressive LDL cholesterol lowering of at least...
- New Data for CRESTOR(R) From STELLAR Trial Presented at American College of...
- Press release article from: PR Newswire April 2, 2003 700+ words
...in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. CONTACT: Gary Bruell of AstraZeneca LP, +1-302-885-1554, gary.bruell@astrazeneca.com Web site: http://www.astrazeneca.com/
- FDA Approves VYTORIN -TM- -ezetimibe/simvastatin-, the First and Only Product...
- Press release article from: Business Wire July 23, 2004 700+ words
...Pharmaceuticals VYTORIN(TM) lowered LDL cholesterol by 52 percent at the recommended starting...simvastatin) for the treatment of high LDL cholesterol (LDL-C) in patients with primary...modifications may require powerful LDL cholesterol lowering-agents and to do this we...
- This Release Was Previously Issued: FDA Approves VYTORIN -TM-...
- Press release article from: Business Wire July 26, 2004 700+ words
...Pharmaceuticals VYTORIN(TM) lowered LDL cholesterol by 52 percent at the recommended starting...simvastatin) for the treatment of high LDL cholesterol (LDL-C) in patients with primary...modifications may require powerful LDL cholesterol lowering-agents and to do this we...
- Average LDL Cholesterol Levels Decreased Approximately 10 Percent Among People...
- Press release article from: PR Newswire October 10, 2005 700+ words
...20051010/NYM064 ) The average serum LDL cholesterol level declined from 123.7 milligrams...2004. The recommended upper limit of LDL cholesterol for people at average risk for heart...Education Program (NCEP). Lowering LDL cholesterol, also known as "bad" cholesterol...
Source: HighBeam Research, Study: Lp-PLA2 predicts coronary heart disease.